



Emerging infections such as parvovirus B19 (B19V) 
have properties indicating the potential to be transmitted 
through blood transfusion.[1-6] The modes of transmission 
of B19V are varied and these include respiratory 
secretions, other routes include vertical transmission from the 
mother to the fetus and through transfusion of B19V-infected 
blood.[7-14]
B19V infection has been closely linked with transient red cell 
aplasia in patients’ with sickle cell anemia (SCA)[15-19] B19V 
infection in pregnant women has also been implicated as a 
cause of hydrops fetalis and intrauterine fetal death.[6,20] Thus, 
there is need to produce protocols for preventing transfusion 
transmissible B19V infection. This study was aimed at 
determining the prevalence of B19V infection amongst blood 
donors in Ogun State, Nigeria.
MaterIals and Methods
We conducted a comparative cross-sectional study among 
eligible blood donors at the donor’s clinic of Olabisi Onabanjo 
University Teaching Hospital (OOUTH), Ogun State from 
February to October 2019. All the donors that participated 
in this study gave a written informed consent and the study 
was approved by the Health and Research Ethical Committee 
of OOUTH (number NHREC/28/11/2017). This study was 
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performed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki and its later amendments. 
Sociodemographic, donation history, and medical history 
data were collected from study participants using interviewer 
administered questionnaire. Thereafter, 5 ml of venous 
blood was obtained from donors and dispensed into an 
anticoagulant-free sample bottle. The sample was centrifuged 
within an hour of collection for 10 min at 3000 rpm to obtain 
serum. The serum was separated into anticoagulant-free bottle 
and stored at −20°C until time for analysis.
B19V immunoglobulin M (IgM) was assayed using Melsin 
enzyme-linked immunosorbent assay (ELISA) kit manufactured 
by Melsin Medical Co., Ltd-Changchun, China. The assay was 
carried out according to the manufacturer’s instruction. The 
result was considered negative if optical density (OD) of sample 
was less than the cutoff. The result was considered positive if 
the OD of sample was ≥ the cutoff. The cutoff calculation was 
the absorbance value of negative control wells +0.15.
Data were analyzed using SPSS software version 23.0 
(Statistical Product and Service Solutions, Inc. Chicago, 
Illinois, USA). Categorical data were summarized using 
frequency and percentages while continuous variables were 
described using the mean and standard deviation or median and 
interquartile range. Pearson’s Chi-square (or Fisher’s exact) 
test was used to test for the association between categorical 
variables and the B19V infection status. Binary logistic 
regression was conducted to evaluate factors associated with 
the B19V infection positivity. The P ≤0.05 was assumed to be 
statistically significant.
results
A total of 183 blood donors were recruited into the study. 
Table 1 shows the socio demographic characteristics of study 
participants. The seroprevalence of anti-IgM B19V amongst 
study participants was 7.1% (95% confidence interval [CI]: 4–11) 
[Figure 1]; there was a statistically significant difference in the 
seropositivity of B19V IgM among the ethnic groups with 
the Yoruba ethnic group having a higher proportion of B19V 
IgM-positive participants P = 0.04 [Table 2]. Although none of 






















Figure 1: Seroprevalence of parvovirus B19 among blood donors
38% of the seropositive participants had a previous history 
of blood donation [Table 2]. The Yoruba ethnic group had an 
increased odds (odds ratio = 2.71, 95% CI = 0.65–11.33) of 
being seropositive for B19V IgM compared to participants from 
other ethnic groups, though this was not statistically significant 
P = 0.22 [Table 3]. Male gender and steady employment 
were also associated with increased odds of infection, while 
increasing age appeared to be protective; though none of these 
factors were statistically significant [Table 3]. Furthermore, 
we found none of the positive participants had clinical 
symptoms of Parvo virus B19 infection as at the time of blood 
donation [Table 4].
dIscussIon
The transfusion of safe blood or blood product is the major 
goal in transfusion medicine. The transmission of viruses 
such as hepatitis B, hepatitis C, HIV have reduced over the 
years due to the global strategy focused on screening these 
viruses in donated blood. There is renewed interest to the 
threat posed by emerging infections that occur due to climate 
and environmental changes or transmigration associated 
with globalization. Emerging infections such as B19V pose 
a threat to transfusion safety especially when the donor is in 
the asymptomatic phase of the infection. In Nigeria, the most 
common emerging infection of paramount concern is B19V 
due to high prevalence of SCA in the population.
Table 1: Characteristics of study participants
Variable Frequency (n=183) Percentage % (95% CI)
Gender
Male 164 89.6 (84-93)
Female 19 10.4 (7-16)
Age group (years)
18-26 41 22.4 (16.90-29.08)
27-35 66 36.1 (29.38- 43.34)
36-43 37 20.2 (14.97-26.73)
44-51 22 12.0 (08.02-17.64)
52-60 17 9.3 (05.83-14.49)
Marital status
Single 65 35.5 (29-30)
Married 118 64.5 (54-75)
Educational status
Informal 7 3.8 (2-8)
Primary 35 19.1 (14-26)
Secondary 84 45.9 (39-53)
Tertiary 57 31.1 (23-41)
Occupation 
Unemployed 54 29.5 (23.3-36.6)
Employed 129 70.5 (63.4-76.7)
Ethnicity
Yoruba 160 87.4 (82-92)
Igbo 13 7.1 (4-12)
Hausa 5 2.7 (1-6)
Others 5 2.7 (1-6)
CI – Confidence interval
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In this study, we found a seroprevalence of 7.1% among 
participants screened for acute B19Vinfection. This result is 
in accordance with that reported by Kumar et al.[21] where a 
prevalence of 7.53% was obtained among blood donors in 
India but higher than most previous studies which reported the 
prevalence of B19V IgM in blood donors or healthy population 
below 2%, as documented by Iheanacho et al., Doyle et al. 
and Muñoz et al. who discovered a prevalence of 1.3%, 1%, 
and 0% among the Nigerian, American, and Spanish blood 
donors, respectively.[22-24] This increase in seroprevalence most 
especially when compared with the study of Iheanacho et al., 
which was conducted in a similar study population suggests 
not enough is being done to prevent active transmission of 
B19V to blood recipients.
We found a significantly higher seropositivity level (P = 0.04) 
among participants in the Yoruba ethnic group compared to the 
other ethnic groups. To the best of our knowledge, this finding 
has not been reported in previous local studies and need to be 
explored in larger nationwide studies for a plausible reason 
for this finding. We also found a higher proportion of males’ 
89.6% (11/13) testing positive for B19V IgM as compared to 
females 10.4% (2/13) in this study, though not significant is 
similar to the result obtained by Musa et al.[25] This attribute 
can possibly be explained by the finding of Faddy et al.[26] 
that females appear to have increased immunity to B19V 
compared to males.
We report reduced odds of B19V IgM seropositivity with 
increasing age, this finding is in keeping with those of various 
studies[26-28] who reported an increase in B19V immunity with 
increasing age among the Nigerian, Indian, and Australian 
population, respectively. From this study, it can be deduced 
that 47.5% of the participants had donated blood before 
and considering the high prevalence of 7.1% obtained from 
the study this suggests a high likelihood of transfusion 
transmissible parvovirus infection upon exposure to affected 
blood products by vulnerable recipients such as sickle cell 
patients, children, pregnant women, and immunocompromised 
patients who may later become chronically infected.
Furthermore, noteworthy is the fact that the positive 
participants were asymptomatic in agreement with the findings 
from Okojokwu et al .,[29]  that there is no statistically significant 
association between symptoms (body rash and joint pains) and 
B19V. This is quite alarming as it suggests a high probability 
of continuous active transmission of transfusion transmissible 
B19V infection.
Key limitations in our study include our small sample size, 
the usage of only one type of ELISA kit and inability to 
carry out molecular assay for confirmation; conducting larger 
multicenter studies will help determine the actual risk of 
transfusion transmissible B19V in the entire general Nigerian 
population.
Table 2: Sociodemographic characteristics of study 
participants based on B19V seroprevalence








Male 11 (84.6) 153 (90) 0.54
Female 2 (15.4) 17 (10)
Age group (years)
18-26 2 (15.4) 39 (22.9) 0.85
27-35 4 (30.8) 62 (36.5)
36-43 4 (30.8) 33 (19.4)
44-51 2 (15.4) 20 (11.8)
52-60 1 (7.7) 16 (9.4)
Marital status
Single 3 (23.1) 62 (36.5) 0.28
Married 10 (76.9) 108  (63.5)
Educational status
Informal 0 (0) 7 (4.1) 0.26
Primary 0 (0) 35 (20.6)
Secondary 8 (61.5) 76 (44.7)
Tertiary 5 (38.5) 52 (30.6)
Occupation
Unemployed 6 48 0.17
Employed 7 122
Ethnicity
Yoruba 10 (76.9) 150 (88.2) 0.04
Igbo 0 (0) 13 (7.6)
Hausa 2 (15.4) 3 (1.8)
Others 1 (7.7) 4 (2.4)
Previous history of blood 
donation
Yes 5 (38.5) 82 (48.2) 0.46
No 8 (61.5) 88 (51.8)
Table 3: Logistic regression model of associations with 
B19V IgM seropositivity
Variable OR (95% CI) P
Age (years)
18-26 1
27-35 0.69 (0.12-4.20) 0.69
36-43 0.39 (0.06-2.37) 0.31
44-51 0.49 (0.06-3.85) 0.49
52-60 0.79 (0.06-9.91) 0.86
Ethnicity
Yoruba 2.71 (0.65-11.33) 0.17
Other ethnic groups 1
Gender




Employed 2.53 (0.73-8.84) 0.49
OR – Odds ratio, CI – Confidence interval
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conclusIon
Although this study showed a low prevalence of B19V 
IgM it still suggests there is an increased risk of transfusion 
transmissible B19V infection by vulnerable population that 
includes pregnant women, immunocompromised, and chronic 
hemolytic anemia patients. This begs the need for improved 
hemovigilance in the country.
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